Open AccessAnti-Lethal Therapy of COVID-19 for Home Health Outpatient Therapy
Author(s) -
Oleg V. Bukhtoyarov,
Denis Mikhailovich Samarin
Publication year - 2021
Publication title -
european journal of medical and health sciences
Language(s) - English
Resource type - Journals
ISSN - 2593-8339
DOI - 10.24018/ejmed.2021.3.4.960
Subject(s) - medicine , pneumonia , intensive care medicine , covid-19 , mechanical ventilation , pharmacotherapy , drug , ceftriaxone , antibiotics , pharmacology , disease , infectious disease (medical specialty) , microbiology and biotechnology , biology
The article presents the rationale for a new therapeutic strategy for treatment of patients with COVID-19, based on the combined use of biologic response modifiers and drugs targeting etiology and pathophysiology of the novel coronavirus infection, excluding disadvantages of polypharmacy, and providing a high clinical effect. This approach has been predominantly used in home health outpatient treatment of 324 patients with COVID-19 of variable severity using the biologic response modifiers “double drug cocktail” made of recombinant human interleukin-2 and recombinant human interferon alpha-2b in combination with alimemazine, nimesulide, rivaroxaban and antibiotic therapy (co-amoxiclav, or ceftriaxone) if secondary bacterial pneumonia was diagnosed. The results obtained indicate a dramatic improvement in the condition of patients, even with a severe COVID-19, which made possible to avoid artificial ventilation and prevent deaths.